AI tool to guide treatment for triple negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing an AI tool that analyzes your tumor tissue to help doctors choose the best treatment before surgery for triple negative breast cancer. It is for people who plan to have chemo or other drugs before their operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with triple negative breast cancer that has not spread beyond the breast or nearby lymph nodes.
- You must be planning to have chemotherapy (or other cancer treatment) before surgery.
- You must agree to donate a small piece of your tumor tissue for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial tests an AI tool that predicts genetic risk for breast cancer. It may help women identified as high-risk by their breast surgeon get quicker genetic counseling.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.